ArticleJournal of nanobiotechnology2024

MiR26a reverses enzalutamide resistance in a bone-tumor targeted system with an enhanced effect on bone metastatic CRPC.

Yuanyuan Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.